Alpha Cognition Inc. (NASDAQ:ACOG – Get Free Report) has received a consensus recommendation of “Buy” from the five analysts that are covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $18.00.
Several equities analysts recently weighed in on ACOG shares. Craig Hallum reissued a “buy” rating and set a $17.00 price objective on shares of Alpha Cognition in a research report on Friday, August 14th. HC Wainwright raised their target price on Alpha Cognition from $18.00 to $20.00 and gave the company a “buy” rating in a report on Monday, August 17th. Wall Street Zen raised Alpha Cognition from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, B. Riley Financial assumed coverage on Alpha Cognition in a report on Thursday, August 20th. They set a “buy” rating and a $21.00 price target for the company.
View Our Latest Stock Analysis on ACOG
Insider Buying and Selling at Alpha Cognition
In related news, Director Robert Wills acquired 10,000 shares of the stock in a transaction dated Friday, August 21st. The shares were acquired at an average price of $9.62 per share, for a total transaction of $96,200.00. Following the completion of the purchase, the director owned 32,241 shares in the company, valued at approximately $310,158.42. The trade was a 44.96% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 8.60% of the company’s stock.
Hedge Funds Weigh In On Alpha Cognition
Several large investors have recently bought and sold shares of ACOG. ACT Capital Partners L.P. acquired a new stake in Alpha Cognition in the 3rd quarter worth $464,000. Pekin Hardy Strauss Inc. acquired a new position in shares of Alpha Cognition during the third quarter valued at about $210,000. Opaleye Management Inc. raised its position in shares of Alpha Cognition by 13.0% during the second quarter. Opaleye Management Inc. now owns 2,895,467 shares of the company’s stock valued at $20,905,000 after buying an additional 333,517 shares during the last quarter. AWM Investment Company Inc. acquired a new position in shares of Alpha Cognition during the second quarter valued at about $12,073,000. Finally, Aristides Capital LLC lifted its stake in shares of Alpha Cognition by 1.4% in the first quarter. Aristides Capital LLC now owns 218,510 shares of the company’s stock valued at $1,200,000 after buying an additional 3,052 shares during the period.
Alpha Cognition Price Performance
Alpha Cognition stock opened at $8.29 on Monday. Alpha Cognition has a fifty-two week low of $4.50 and a fifty-two week high of $10.14. The firm has a fifty day moving average price of $8.80 and a two-hundred day moving average price of $7.21. The firm has a market cap of $180.56 million, a price-to-earnings ratio of -7.54 and a beta of 2.32.
Alpha Cognition (NASDAQ:ACOG – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.01). The business had revenue of $6.00 million during the quarter, compared to analyst estimates of $4.38 million. Alpha Cognition had a negative net margin of 153.61% and a negative return on equity of 54.60%. As a group, sell-side analysts expect that Alpha Cognition will post -1.38 earnings per share for the current year.
Alpha Cognition Company Profile
Alpha Cognition Inc is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative diseases and cognitive disorders. The company’s work is centered on therapies intended to address the medical needs of patients with Alzheimer’s disease and other conditions affecting cognition.
Its lead commercial product is ZUNOVO (galantamine hydrobromide) extended-release capsules, an orally administered treatment approved by the U.S. Food and Drug Administration for mild-to-moderate dementia of the Alzheimer’s type.
Further Reading
- Five stocks we like better than Alpha Cognition
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
